DK1734987T3 - Interferon-beta til antivirusbehandling af respiratoriske sygdomme - Google Patents

Interferon-beta til antivirusbehandling af respiratoriske sygdomme

Info

Publication number
DK1734987T3
DK1734987T3 DK05708482.4T DK05708482T DK1734987T3 DK 1734987 T3 DK1734987 T3 DK 1734987T3 DK 05708482 T DK05708482 T DK 05708482T DK 1734987 T3 DK1734987 T3 DK 1734987T3
Authority
DK
Denmark
Prior art keywords
agent
interferon beta
respiratory diseases
treatment
virus treatment
Prior art date
Application number
DK05708482.4T
Other languages
Danish (da)
English (en)
Inventor
Donna Elizabeth Davies
Peter Alexander Blanch Wark
Stephen Holgate
Sebastian L Johnston
Original Assignee
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southampton filed Critical Univ Southampton
Application granted granted Critical
Publication of DK1734987T3 publication Critical patent/DK1734987T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DK05708482.4T 2004-03-12 2005-03-07 Interferon-beta til antivirusbehandling af respiratoriske sygdomme DK1734987T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0405634.7A GB0405634D0 (en) 2004-03-12 2004-03-12 Anti-virus therapy for respiratory diseases
PCT/GB2005/050031 WO2005087253A2 (en) 2004-03-12 2005-03-07 Interferon-beta for anti-virus therapy for respiratory diseases

Publications (1)

Publication Number Publication Date
DK1734987T3 true DK1734987T3 (da) 2010-08-30

Family

ID=32117582

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05708482.4T DK1734987T3 (da) 2004-03-12 2005-03-07 Interferon-beta til antivirusbehandling af respiratoriske sygdomme

Country Status (12)

Country Link
US (3) US7569216B2 (https=)
EP (2) EP2206512A3 (https=)
JP (2) JP4807526B2 (https=)
AT (1) ATE466591T1 (https=)
CA (2) CA2558212C (https=)
DE (1) DE602005021078D1 (https=)
DK (1) DK1734987T3 (https=)
ES (1) ES2343732T3 (https=)
GB (1) GB0405634D0 (https=)
PL (1) PL1734987T3 (https=)
PT (1) PT1734987E (https=)
WO (1) WO2005087253A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
US8318423B2 (en) * 2004-07-06 2012-11-27 Focus Diagnostics, Inc. Methods and compositions for detecting rhinoviruses
CA2622016A1 (en) * 2005-09-09 2007-03-15 Imperial Innovations Limited Interferon lambda therapy for treatment of respiratory diseases
BRPI0520564A2 (pt) 2005-09-20 2009-05-19 Univ New York método de tratar doença pulmonar com interferons apoio governamental
DE102006022877B4 (de) * 2006-05-15 2009-01-29 Sartorius Stedim Biotech Gmbh Verfahren zur Bestimmung der Viabilität von Zellen in Zellkulturen
US7871603B2 (en) 2007-05-18 2011-01-18 Synairgen Research Limited Interferon-beta and/or lambda for use in treating rhinovirus infection in the elderly
GB0713402D0 (en) * 2007-07-11 2007-08-22 Cardiff & Vale Nhs Trust A method of diagnosing a condition using a neural network
EP2220115A2 (en) * 2007-12-13 2010-08-25 Glaxo Group Limited Polypeptides, antibody variable domains & antagonists
EP2373329A4 (en) * 2008-12-19 2012-07-04 Univ California USE OF INGREDIENTS OF THE EPIDERMAL GROWTH FACTOR IN THE TREATMENT OF VIRUS INFECTIONS
WO2011067759A1 (en) * 2009-12-02 2011-06-09 Neetour Medical Ltd. Hemodynamics-based monitoring and evaluation of a respiratory condition
RS55154B1 (sr) * 2010-03-12 2017-01-31 Synairgen Res Ltd Interferon beta za upotrebu u lečenju bolesti donjeg respiratornog trakta uzrokovane gripom
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
CN109293782A (zh) 2014-01-08 2019-02-01 德益阳光生物技术（北京）有限责任公司 融合多肽及使用方法
JP7317796B2 (ja) 2017-07-24 2023-07-31 ノババックス，インコーポレイテッド 呼吸器疾患を治療するための方法および組成物
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
US20220233643A1 (en) * 2019-02-13 2022-07-28 University Of Florida Research Foundation, Incorporated TARGETING LUNG-RESIDENT TNFR2+ cDC2 (R2D2) SUBPOPULATION TO TREAT ASTHMA
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
EP4181944A1 (en) 2020-07-20 2023-05-24 Synairgen Research Limited Inhaled interferon-beta for improving outcome in sars-cov-2 infected patients
GB202014114D0 (en) 2020-09-08 2020-10-21 Synairgen Res Ltd Use of inhaled interferon-beta to treat virus-induced exacerbations in copd patients undergoing treatment with a systemic corticosteroid
WO2022096582A1 (en) * 2020-11-04 2022-05-12 Ethris Gmbh Use of ifn-lambda mrna for treating viral infections
EP4292604A4 (en) * 2021-01-13 2024-12-18 Abion Inc. METHOD OF PROPHYLACTIC ADMINISTRATION AGAINST A RESPIRATORY VIRUS, COMPRISING THE ADMINISTRATION OF INTERFERON BETA TO A SUBJECT POTENTIALLY INFECTED WITH A RESPIRATORY VIRUS

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596260B1 (en) * 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
MX9605717A (es) * 1994-05-18 1998-05-31 Inhale Therapeutic Syst Metodos y composiciones para la formulacion de polvo seco de interferones.
US6030609A (en) 1995-05-19 2000-02-29 Case Western Reserve University Method and composition for treating paramyxovirus
US20010031253A1 (en) * 1996-07-24 2001-10-18 Gruenberg Micheal L. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
AU780270B2 (en) * 2000-02-23 2005-03-10 Association Francaise Contre Les Myopathies Treatment of immune diseases
GB2362884A (en) 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
EP1334128A2 (en) 2000-11-02 2003-08-13 Maxygen Aps New multimeric interferon beta polypeptides
US20030091544A1 (en) * 2001-03-13 2003-05-15 Vical Incorporated Interferon-Beta polynucleotide therapy for autoimmune and inflammatory diseases
WO2003066002A2 (en) 2002-02-08 2003-08-14 University Of Medicine And Dentistry Of New Jersey IFN-a/b-INDEPENDENT MECHANISM OF ANTIVIRAL PROTECTION
US20040037809A1 (en) * 2002-06-28 2004-02-26 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon beta
CA2503305A1 (en) 2002-10-23 2004-05-06 Zymogenetics, Inc. Methods for treating viral infection using il-28 and il-29
EP2251352A1 (en) 2003-08-07 2010-11-17 ZymoGenetics, L.L.C. Homogeneous preparations of IL-28 and IL-29
GB0405634D0 (en) 2004-03-12 2004-04-21 Univ Southampton Anti-virus therapy for respiratory diseases
JP4896005B2 (ja) 2004-04-02 2012-03-14 ザイモジェネティクス リミテッド ライアビリティ カンパニー Ｉｌ−２８およびｉｌ−２９システイン変異体を用いるウイルス感染を治療するための方法

Also Published As

Publication number Publication date
EP1734987A2 (en) 2006-12-27
JP2011144201A (ja) 2011-07-28
PL1734987T3 (pl) 2010-10-29
US20130209399A1 (en) 2013-08-15
EP2206512A2 (en) 2010-07-14
US20090257980A1 (en) 2009-10-15
US8273342B2 (en) 2012-09-25
PT1734987E (pt) 2010-07-06
CA2558212C (en) 2012-11-27
JP4807526B2 (ja) 2011-11-02
DE602005021078D1 (de) 2010-06-17
CA2787978A1 (en) 2005-09-22
EP1734987B1 (en) 2010-05-05
WO2005087253A3 (en) 2005-11-24
JP2007528890A (ja) 2007-10-18
WO2005087253A2 (en) 2005-09-22
EP2206512A3 (en) 2013-01-09
US20070134763A1 (en) 2007-06-14
HK1097181A1 (en) 2007-06-22
ES2343732T3 (es) 2010-08-09
ATE466591T1 (de) 2010-05-15
GB0405634D0 (en) 2004-04-21
CA2558212A1 (en) 2005-09-22
US9089535B2 (en) 2015-07-28
US7569216B2 (en) 2009-08-04

Similar Documents

Publication Publication Date Title
DK1734987T3 (da) Interferon-beta til antivirusbehandling af respiratoriske sygdomme
CY1108326T1 (el) ΝΕΟΣ ΣΥΝΔΥΑΣΜΟΣ ΑΝΤΙΧΟΛΙΝΕΡΓΙΚΩΝ ΚΑΙ β ΜΙΜΗΤΙΚΩΝ ΓΙΑ ΤΗΝ ΘΕΡΑΠΕΙΑ ΑΝΑΠΝΕΥΣΤΙΚΩΝ ΑΣΘΕΝΕΙΩΝ
MX2009013138A (es) Polipeptidos, dominios variables de anticuerpo y antagonistas.
WO2008149144A3 (en) Polypeptides, antibody variable domains and antagonists
DE602005026007D1 (de) Opioide zur behandlung von chronisch-obstruktiver lungenerkrankung (copd)
WO2006086107A3 (en) Methods and compositions for minimizing accrual of inhalable insulin in the lungs
MA33818B1 (fr) Nouveaux antagonistes du récepteur ccr2 et leurs utilisations
LTC1562603I2 (lt) Nauji vaistai, skirti lėtinių obstrukcinių plaučių ligų gydymui
NO20070651L (no) Sammensetninger av statiner med bronkodilatorer
ATE421325T1 (de) Kombination von methylxanthinverbindungen und steroiden zur behandlung chronischer atemwegserkrankungen
UA83813C2 (ru) Порошковое лекарственное средство, которое содержит соль тиотропия и ксинафоат салметерола
JP2011144201A5 (https=)
EA200700037A1 (ru) Производные n-гидроксиамида и их применение
IL199022A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
MX2007012700A (es) Compuestos organicos.
CY1108420T1 (el) Προτοτυπο τιοτροπιουχο κονιωδες σκευασμα για εισπνοη
NO20073909L (no) Forstover-formulering
JP2005527570A5 (https=)
ITMI20060158U1 (it) Apparecchiatura per la somministrazione di ossigeno o di aria addizionata da ossigeno,per terapie respiratorie.
WO2007029041A3 (en) Interferon lambda therapy for treatment of respiratory diseases
DK1511466T3 (da) Anvendelse af glycosaminoglycaner, såsom for eksempel heparin, til behandling af respirationslidelser, såsom COPD
EA200501625A1 (ru) Интерферон-бета при тяжелом остром респираторном синдроме (sars)
Tiwari et al. C71 YOU ARE WHAT YOU BREATHE: AIRWAY CELL BIOLOGY IN COPD: P53-And Pai-1-Mediated Induction Of CXC Chemokines And Cxcr2: Importance In Pulmonary Inflammation Due To Cigarette Smoke Exposure
Marsh et al. B106 CELLULAR/MOLECULAR MECHANISMS AND TRANSLATIONAL ASPECTS OF RESPIRATORY TRACT INFECTIONS: The Role Of Pellino-1 In Modulating Signalling Pathways Controlling The Inflammatory Response To Viral Stimuli In Airway Epithelial Cells